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Purpose. To determine the eﬀect of simple use of suppository povidone-iodine on infectious complications after transrectal
ultrasonography-guided biopsy of the prostate. Methods. All 481 patients are included and received antibiotic prophylaxis. Among
them, 360 patients received povidone-iodine suppository (Gynobetadine; 200mg) immediately prior to biopsy and 121 patients
did not. Infectious complications were classiﬁed. To evaluate bactericidal eﬀects, we counted bacterial colonies in the rectum,
harvested from a rectal swab before insertion of the suppository and after biopsy. Aliquots of the suspended bacterial strains
were added to Mueller-Hinton agar medium for incubation. Colony counts were determined. Results. Infectious complications
developed in 1 case (0.3%) in the rectal preparation group (Group 1) and in 8 cases (6.6%) in the nonrectal preparation group
(Group 2). One in Group 1 had a fever without sepsis. Two patients had sepsis and six had fever without sepsis in Group 2. Rectal
preparationwas astatisticallysigniﬁcant riskfactorinﬂuencingthedevelopment ofinfectiouscomplications. Invitroexperiments,
the mean number of colony-forming units decreased 99.9% after the rectal povidone-iodine preparation. Conclusions. All through
the biopsy, povidone-iodine melted into the rectum and decreased the bacterial colony count. Simple use of povidone-iodine
suppository before prostate biopsy minimizes the risk of infectious complications.
Copyright © 2009 Dong Soo Park et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Since the introduction of PSA as a marker in the diagnosis of
prostate cancer, the rate of biopsies taken from the prostate
has increased dramatically. Although prostate biopsies are
generally considered a safe procedure, complications sec-
ondary to biopsy are some of the most common adverse
events encountered in practice. Usually minor and self-
limiting,theyareoccasionallyseriousandevenfatal.Amajor
problem of the transrectal approach is the risk of infection,
leading to febrile reactions, epididymitis, prostatitis, sepsis,
and even death. Currently, many urologists use prophylactic
antibiotic therapy to minimize the infectious complications
after biopsy, but these therapies do not completely eliminate
the incidence of infection [1, 2]. For this reason, a rectal
preparation has been used as a cleansing technique before
biopsy to reduce infectious complications [1–3]. However,
the eﬀect of a rectal preparation applied before biopsy has
not yet been validated. We therefore determined the eﬀect
of povidone-iodine suppository (Gynobetadine) prophylaxis
on infectious complications after transrectal needle biopsy of
the prostate.
2.MaterialandMethods
This study was performed on 481 patients in our hospital
from January 2004 to December 2007 who had indications
for a prostate biopsy, including an elevated PSA, hypoechoic
lesions on ultrasonography, or abnormal digital rectal ﬁnd-
ings.
All patients received antibiotic prophylaxis consisting
of a single intravenous injection of a 3rd generation2 Advances in Urology
cephalosporin just before biopsy and oral administration of
ceﬁxime (100mg twice daily) at morning of day of biopsy
and then continued for 5 days thereafter. Between April
2005 and December 2007, 360 patients (group 1) received
a povidone-iodine suppository (Gynobetadine; 200mg) just
before biopsy, and between January 2004 and March 2005
121 patients (group 2) did not receive Gynobetadine. All
patients were provided with informed consent before the
biopsy. Transrectal ultrasound (TRUS-) guided prostate
biopsies were performed without anesthesia in an outpatient
setting by experienced urology doctors. 12 cores were
obtained in the same way between two groups. An Aloka
Prosound SSO-4000 ultrasonography unit and a transrectal
7.5MHz biplane probe were used during the procedure.
Biopsies were taken with an 18G ASAP automatic biopsy
needle (SACN Biopsy Needle). At the one week followup
visit, any complications after the biopsy were evaluated and
recorded.
Infectious complications were classiﬁed as sepsis, fever
(temperature higher than 38
◦C) without sepsis, and other
clinical infections. Sepsis was deﬁned as two or more of the
following conditions as a result of infection: body temper-
ature >38◦Co r<36◦C, heart rate >90 beats per minute,
respiration rate >20 breaths per minute or arterial partial
pressure of carbon dioxide <32mmHg, and white blood
cell count >12000cells/cm3 or <4000cells/cm3,o r>10%
immature (band) forms [4]. Noninfectious complications
were evaluated and classiﬁed as hematuria, rectal bleeding,
and perineal pain.
To evaluate the bactericidal eﬀects of Gynobetadine, we
counted bacterial colonies in the rectum that had been har-
vested from rectal swab before the insertion of Gynobetadine
and after biopsy. Colony counts were determined by agar
dilution. Bacterial strains of the rectal swab were suspended
and diluted in sterile saline, and aliquots of this suspension
wereadded to Mueller-Hintonagarmedium. After overnight
incubation, the colony counts were determined.
3. Results
The mean ages of groups 1 and 2 patients were 64.6
years (range, 29–88 years) and 65.7 years (range, 31–96
years), respectively. The PSA levels in groups 1 and 2
were 6.45ng/mL and 7.34ng/mL, , respectively. The patient
demographic data and complications are shown in Table 1.
There was no statistically signiﬁcant diﬀerence between
groups 1 and 2 with respect to demographic data.
Infectious complications developed in 8 cases (6.6%) in
the nonrectal preparation group (group 2) and in 1 case
(0.3%) in the rectal preparation group (group 1). Among
eight infectious complications in the nonrectal preparation
group, two patients had sepsis and six patients had fever
without sepsis. Among the eight patients, four patients
developed an acute bacterial prostatitis and one patient
developed an acute epididymitis. One patient from group I
complained of a febrile sensation one day after biopsy, which
resolved spontaneously. A single rectal preparation using
Gynobetadine signiﬁcantly lowered the risk of development
Table 1: Demographic data of patients.
Group 1 Group 2
Number of patients 360 121
Mean age (years) 64.6 (29–88) 65.7 (31–96)
Average PSA (ng/mL) 6.45 7.34








Rectal bleeding 5 4
Perineal pain 7 5
∗P = .001; †P = .391.
Table 2: Colony counts before insertion of povidone-iodine and
after biopsy.
Plate no. Before After
11 .19 ×105 5.0 ×102
21 .93 ×104 < 3.0 ×101
31 .09 ×104 < 3.0 ×101
47 .0 ×103 3.6 ×101
57 .0 ×105 < 3.0 ×101
67 .4 ×104 4.0 ×102
∗P = .002.
of infectious complications (P = .001). In in vitro experi-
ments, the mean number of colony-forming units decreased
99.9% after rectal preparation (Table 2). We found that the
bacterial colony count before rectal preparation ranged from
7.0 × 103 to 7.0 × 105, but decreased to <3.0×101 after
biopsy. Figure 1 shows the bactericidal eﬀects of povidone-
iodine,anditisclearthatthebacterialcountwassigniﬁcantly
reduced after the insertion of Gynobetadine. The Gynobe-
tadine preparation statistically decreased the colony count
(P = .002).
Noninfectious complications (classiﬁed as hematuria,
rectal bleeding, and perineal pain) developed in 22 cases
(18.2%) in the nonrectal preparation group and in 29 cases
(8.1%) in the rectal preparation group. The noninfectious
complications were self-limiting and did not require inter-
vention or transfusion. No patient developed urinary reten-
tion after the procedure. There was no statistically signiﬁcant
diﬀerence in terms of noninfectious complications.
4. Discussion
Transrectal prostate biopsy with ultrasonography is the gold
standard in the diagnosis of prostate cancer. Most men
undergoing prostate biopsy are otherwise healthy. The pro-
cedure, however, is not harmless. Transient side events, such
as local pain, hematuria, hemospermia, dysuria, and rectal
bleeding have been reported in a large number of patients [5,
6]. Bacteriuria occurs in 20–53% and bacteremia in as many
as 73% of patients following a biopsy of the prostate [7, 8],Advances in Urology 3
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Figure 1: In in vitro experiments (a) bacterial colony plate in
an agar dilution before insertion of povidone-iodine. (b) Bacterial
colony plate in an agar dilution after biopsy; the mean number of
colony-forming units decreased 99.9% after rectal preparation.
andrectalbleedinghasbeenreportedin75%ofsuchpatients
[2–4]. Fever associated with genitourinary symptoms is
d e s c r i b e di n3 – 1 0 %a n ds e p t i c e m i ai n<5% of patients
followingabiopsyoftheprostate[7–9].Antimicrobialagents
lower the incidence of postbiopsy infectious complications
[1, 9, 10]. Most urologists agree in the necessity of antibiotic
prophylaxis,butthetiming, durationoftheregimen,andthe
route of administration remain controversial [11]. In most
studies, an antibiotic regimen of at least 3 days has been used
[12].
Despite the use of prophylactic antibiotics, the develop-
ment of infectious complications after biopsy remains possi-
ble, although its incidence is low [1, 13, 14]. For this reason,
a cleansing rectal enema has been used by 81% of urologists
as a means to reduce infectious complications [15]. Most
investigators believe that rectal preparation reduces the
rate of bacteremia [16, 17]. In a prospective randomized
study, Lindert et al. [8] proposed that bacteremia might be
minimized by a prebiopsy enema. In their study, bacteremia
followingprostatebiopsyoccurredin4%(1of25)ofpatients
who had prebiopsy enemas compared with 28% (7 of 25)
of those who did not. This study therefore provided a
theoretical basis for using a prebiopsy rectal preparation for
the prevention of infectious complications.
Povidone-iodine also may be used to prepare the rectum
for transrectal biopsy of the prostate intraoperatively. The
use of povidone-iodine is well known in clinical medical
practice. Its use in dermatology and surgery as a disinfectant
is ubiquitous and is based on the fact that povidone-iodine
has broad-spectrum antimicrobial activity [18], including
viruses [19], fungi [20], and parasites, as well as anti-
inﬂammatory activity [21]. Povidone-iodine is an antiseptic
solution extensively used in diﬀerent concentrations.
Brown et al. [16] reported that a povidone-iodine
enema provided a safe and eﬀective means for preventing
bacteremia and bacteriuria and Melekos [17] showed that
parenteral piperacillin in combination with a povidone-
iodineenemasigniﬁcantlyreducestheincidenceofinfectious
complications. Khan et al. [22] reported that intraoperative
preparation of the rectum with a povidone-iodine-saturated
gauze during transrectal biopsy of prostate decreased the
incidence of bacteriuria and bacteremia. Akay et al. [23]
reported that lavage with Betadine prior to transrectal
prostate biopsy is adequate in the prevention of infectious
complications.
Huang et al. [24] reported that a phosphate-based enema
combined with povidone-iodine is eﬀective in reducing
postprostate biopsy infectious complications (9.23 versus
0%).
A povidone-iodine suppository (Gynobetadine; 200mg)
is more eﬀective than a povidone-iodine enema, because the
contact surface between the rectal mucosa of the prostate
area is more constant during the biopsy procedure than
with the enema. With the enema technique, the solution of
povidone-iodine is retained in the dependent portion of the
rectum and may not eﬀectively bathe the rectal mucosa of
the prostatic area. A povidone-iodine suppository has better
patient acceptance than an enema.
There have been some reports that have shown the
eﬀects of povidone-iodine in the treatment of infectious
complications [22]. However, there are no studies that have
veriﬁed the bactericidal eﬀects of povidone-iodine in in vitro
experiments. For this reason, we counted bacterial colonies
in the rectum that had been harvested from rectal swabs
before the insertion of povidone-iodine and after biopsy
to evaluate the bactericidal eﬀects of povidone-iodine. We
found that the bacterial colony counts before the rectal
preparation were decreased dramatically after biopsy. These
local antiseptic precautions seem worthwhile. With the large
reduction in microorganisms, contamination is likely to be
considerably reduced.
Periprostatic local anesthesia for transrectal ultrasound-
guided prostate biopsy is known to reduce pain but increases
the incidence of bacteriuria and bacteremia [25]. Using our
techniquewithpovidone-iodine,localanesthesiaforprostate
biopsy is eﬀective and safe for those in which it is necessary.
According to the data obtained in the present study, it is
apparent that a Gynobetadine rectal preparation is reliable in
preventing infection. Other anti-infectious enemas increase
patient cost and discomfort [26]. The cost of Gynobetadine
isverylow(approximatelyUS$0.50),anditiscomfortableto
patients by reason of quick and easy delivery. And it is better
tolerated to the patients. After our prospective randomized
trial with iodine suppository considered, we conclude that
the povidone-iodine suppository is important to protect4 Advances in Urology
against infectious complications in patients undergoing
biopsy of the prostate.
5. Conclusions
Simple rectal preparation using a povidone-iodine suppos-
itory was a statistically signiﬁcant risk factor for infectious
complications after prostate biopsy in our study.
Thus, we recommend a povidone-iodine suppository
(200mg)rectalpreparationbeforeprostatebiopsybecauseof
itseﬀectivenessincontrollingrectalbacterialcolony-forming
units and species, its very low cost, and its availability.
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